- Home
- A-Z Publications
- Current Molecular Medicine
- Previous Issues
- Volume 16, Issue 1, 2016
Current Molecular Medicine - Volume 16, Issue 1, 2016
Volume 16, Issue 1, 2016
-
-
Development of New Therapeutic Agents for Fibrodysplasia Ossificans Progressiva.
Authors: Y. Luo, A. Alsamarah, K. Zhang and J. HaoFibrodysplasia ossificans progressiva (FOP, MIM #135100) is a rare genetic disorder of heterotopic endochondral ossification, resulting in transformation of soft tissue into episodic bone formation. Currently, no effective treatment for FOP has been established. The causative heterozygous genetic mutations have been identified in either the intracellular glycine-serine-rich (GS) domain or kinase domain of ALK2 Read More
-
-
-
Calreticulin in the Heart: From Embryological Development to Cardiac Pathology.
Authors: D. Martinho-Dias, A. Leite-Moreira and P. Castro-ChavesBackground: Calreticulin is a Ca2+-binding chaperone in the endoplasmic reticulum (ER) which is crucial to the correct embryological development of the heart in mice. Altered expression levels in the adult were correlated with several cardiac pathologies such as cardiac hypertrophy and dilated cardiomyopathy. Aim: In this review, we aim to describe the role of calreticulin in the embryological development of the heart in mice an Read More
-
-
-
Modulation of intracellular pH in human ovarian cancer.
Authors: C. Sanhueza, J. Araos, L. Naranjo, R. Villalobos, F. Westermeier, C. Salomon, A.R. Beltrán, M.A. Ramírez, J. Gutiérrez, F. Pardo, A. Leiva and L. SobreviaTo sustain tumor growth, the cancer cells need to adapt to low levels of oxygen (i.e., hypoxia) in the tumor tissue and to the tumor-associated acidic microenvironment. In this phenomenon, the activation of the sodium/proton exchanger 1 (NHE1) at the plasma membrane and the hypoxia-inducible factor (HIF) are critical for the control of the intracellular pH (pHi) and for hypoxia adaptation, respectively. Interestingly, both Read More
-
-
-
Vagus nerve stimulation in treating depression: A tale of two stories.
Authors: T.-F. Yuan, A. Li, X. Sun, O. Arias-Carrión and S. MachadoVagus nerve stimulation (VNS) has been widely used to treat different neurological disorders, especially epilepsy. Accumulating evidence also suggests its potential application in antidepressive therapy, given that VNS has been confirmed by several clinical trials to exert long-term effects on mitigating depression and reducing the risk of relapse in depressed patients. Likewise, VNS has also proven to ameliorate the behavi Read More
-
-
-
Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy.
Authors: S. Saichaemchan, W. Ariyawutyakorn and M. Varella-GarciaThe family of fibroblast growth factor (FGFs) and their receptors (FGFRs) regulates vital roles in many biological processes affecting cell proliferation, migration, differentiation and survival. Deregulation of the FGF/FGFR signaling pathway in cancers has been better understood and the main molecular mechanisms responsible for the activation of this pathway are gene mutations, gene fusions and gene amplification. DN Read More
-
-
-
Jade-1: its structure, regulation and functions in the renal cancer.
Authors: Y.-C. Zhang, W.-Q. Du, R.-Y. Zhang, J.-N. Zheng and D.-S. PeiJade-1 is originally identified by the yeast two-hybrid system as a protein partner of von Hippel-Lindau (pVHL) tumor suppressor, a well-known renal tumor suppressor. In cellular signaling pathways, many upstream Jade-1 regulators, such as pVHL, CK1α, PC1, and NPHP4, can control its activity by stabilization, phosphorylation, and nuclear translocation. Numerous downstream effectors, including β-catenin, AKT, p21, and Bcl-2, are Read More
-
-
-
The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.
More LessObjective: We investigated mechanisms of colorectal cancer (CRC) chemoresistance to first-line chemotherapy (capecitabine plus oxaliplatin (XELOX)) and identified two putative chemoresistant microRNAs, miR-1914* and -1915, that are downregulated in plasma samples from patients with chemoresistant CRC. Methods: A number of plasma samples from CRC patients were analyzed for the levels of miR-1914* and - 191 Read More
-
-
-
Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
Authors: G. Zhou, J. Yu, A. Wang, S.-H. Liu, J. Sinnett-Smith, J. Wu, R. Sanchez, J. Nemunaitis, C. Ricordi, E. Rozengurt and F.C. BrunicardiPancreatic ductal adenocarcinoma (PDAC) is one of the most potent and perilous diseases known, with a median survival rate of 3-5 months due to the combination of only advanced stage diagnosis and ineffective therapeutic options. Metformin (1,1-Dimethylbiguanide hydrochloride), the leading drug used for type 2 diabetes mellitus, emerges as a potential therapy for PDAC and other human cancers. Metformin exerts its Read More
-
-
-
DREADD in Parvalbumin Interneurons of the Dentate Gyrus Modulates Anxiety, Social Interaction and Memory Extinction
Parvalbumin (PV)-positive interneurons in the hippocampus play a critical role in animal memory, such as spatial working memory. However, how PV-positive interneurons in the subregions of the hippocampus affect animal behaviors remains poorly defined. Here, we achieved specific and reversible activation of PV-positive interneurons using designer receptors exclusively activated by designer drugs (DREADD) technology. Read More
-
Volumes & issues
-
Volume 25 (2025)
-
Volume 24 (2024)
-
Volume 23 (2023)
-
Volume 22 (2022)
-
Volume 21 (2021)
-
Volume 20 (2020)
-
Volume 19 (2019)
-
Volume 18 (2018)
-
Volume 17 (2017)
-
Volume 16 (2016)
-
Volume 15 (2015)
-
Volume 14 (2014)
-
Volume 13 (2013)
-
Volume 12 (2012)
-
Volume 11 (2011)
-
Volume 10 (2010)
-
Volume 9 (2009)
-
Volume 8 (2008)
-
Volume 7 (2007)
-
Volume 6 (2006)
-
Volume 5 (2005)
-
Volume 4 (2004)
-
Volume 3 (2003)
-
Volume 2 (2002)
-
Volume 1 (2001)
Most Read This Month
Article
content/journals/cmm
Journal
10
5
false
en
